India, April 15 -- Aurigene Pharmaceutical Services, an integrated drug discovery and CDMO partner and subsidiary of Dr. Reddy's Laboratories, has announced progress in its research collaboration with US-based Alveus Therapeutics, a biotechnology company developing next-generation therapies for obesity and metabolic diseases.

Under the collaboration, Aurigene provides integrated drug discovery services supporting Alveus' research programmes in metabolic disease. It combines Alveus' expertise in metabolic biology and therapeutic strategy with Aurigene's discovery capabilities, including computational design, medicinal chemistry, and integrated biology platforms.

The teams nominated ALV-200, a highly selective AMYR3 peptide candidate for ...